[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20050948A1 - Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv - Google Patents

Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv

Info

Publication number
PE20050948A1
PE20050948A1 PE2004000875A PE2004000875A PE20050948A1 PE 20050948 A1 PE20050948 A1 PE 20050948A1 PE 2004000875 A PE2004000875 A PE 2004000875A PE 2004000875 A PE2004000875 A PE 2004000875A PE 20050948 A1 PE20050948 A1 PE 20050948A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
carbamoil
inhibitors
trans
amino
Prior art date
Application number
PE2004000875A
Other languages
English (en)
Inventor
Kota Asahina
Yuki Kitao
Satoru Kobayashi
Kenichi Matsui
Masaki Yamashita
Hisashi Shinkai
Toshio Taniguchi
Kazuhiro Tsutsumi
Tomohiro Oda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34317220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20050948A1 publication Critical patent/PE20050948A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CARBAMOIL-AMINA DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOALQUILO (C3-C12) OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), OPCIONALMENTE SUSTITUIDOS; R3 ES CICLOALQUILO(C3-C12) OPCIONALMENTE SUSTITUIDO; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), HETEROCICLO SATURADO DE 3 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 2-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METILACARBAMOIL)METIL]CICLOHEXILMETOXIMETIL}BENZOICO, ACIDO 3-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METIL-CARBAMOIL)METIL]CICLOHEXILMETOXIMETIL-5-DIMETILAMINOBENZOICO, (2-METANOSULFONIL)FENILAMIDA DE ACIDO TRANS 4-[(S)-AMINO-(N-CICLOBUTIL-N-METILCARBAMOIL)METIL]CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL PEPTIDASA DPP-IV, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE LA DIABETES TIPO II, OBESIDAD O SIMILARES
PE2004000875A 2003-09-09 2004-09-09 Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv PE20050948A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003317407 2003-09-09
JP2003395879 2003-11-26
JP2004114685 2004-04-08

Publications (1)

Publication Number Publication Date
PE20050948A1 true PE20050948A1 (es) 2005-12-16

Family

ID=34317220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000875A PE20050948A1 (es) 2003-09-09 2004-09-09 Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv

Country Status (4)

Country Link
AR (1) AR046330A1 (es)
PE (1) PE20050948A1 (es)
TW (1) TW200530157A (es)
WO (1) WO2005025554A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007027225A2 (en) * 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
KR20090004950A (ko) 2006-04-12 2009-01-12 프로비오드룩 아게 효소 억제제
PT2056815E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
EP2351744B1 (en) 2008-10-17 2015-01-07 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
MX337575B (es) * 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011270832B2 (en) 2010-06-24 2016-05-12 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
WO2012154678A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic sulfonamide compounds and methods of making and using same
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR20140112566A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
EP2925737B1 (en) 2012-11-05 2017-06-14 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
MA41587A (fr) 2014-12-17 2021-04-28 Pimco 2664 Ltd N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique
NZ771435A (en) 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
CA3018344A1 (en) * 2016-04-04 2017-10-12 Research Triangle Institute Neuropeptide s receptor (npsr) agonists
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US10683267B1 (en) * 2019-11-21 2020-06-16 King Abdulaziz University Antidiabetic compounds
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
SE9701245D0 (sv) * 1997-04-04 1997-04-04 Bjoern Classon Antivirals
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2003029200A2 (en) * 2001-10-02 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7727964B2 (en) * 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes

Also Published As

Publication number Publication date
WO2005025554A3 (en) 2005-07-28
TW200530157A (en) 2005-09-16
WO2005025554A2 (en) 2005-03-24
AR046330A1 (es) 2005-12-07

Similar Documents

Publication Publication Date Title
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20060921A1 (es) Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20071326A1 (es) Inhibidores de la polimerasa viral
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
AR073348A1 (es) Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20050864A1 (es) Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
GT200800242A (es) Derivados biciclicos como inhibidores de cetp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal